A beta version of life

p110β takes center stage.

Hashem A. Dbouk, Jonathan M. Backer

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

Original languageEnglish (US)
Pages (from-to)729-733
Number of pages5
JournalOncotarget
Volume1
Issue number8
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Neoplasms
Carcinogenesis
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A beta version of life : p110β takes center stage. / Dbouk, Hashem A.; Backer, Jonathan M.

In: Oncotarget, Vol. 1, No. 8, 12.2010, p. 729-733.

Research output: Contribution to journalArticle

Dbouk, HA & Backer, JM 2010, 'A beta version of life: p110β takes center stage.', Oncotarget, vol. 1, no. 8, pp. 729-733.
Dbouk, Hashem A. ; Backer, Jonathan M. / A beta version of life : p110β takes center stage. In: Oncotarget. 2010 ; Vol. 1, No. 8. pp. 729-733.
@article{5b7882e128d64a55ae5b25868f160c3d,
title = "A beta version of life: p110β takes center stage.",
abstract = "The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.",
author = "Dbouk, {Hashem A.} and Backer, {Jonathan M.}",
year = "2010",
month = "12",
language = "English (US)",
volume = "1",
pages = "729--733",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "8",

}

TY - JOUR

T1 - A beta version of life

T2 - p110β takes center stage.

AU - Dbouk, Hashem A.

AU - Backer, Jonathan M.

PY - 2010/12

Y1 - 2010/12

N2 - The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

AB - The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=79958016002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958016002&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 729

EP - 733

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -